LAX.SH
MOREPEN LAB. LTD·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
117.67
+1.94%52W Range
Market Cap
₹6,447.77 Cr
Traded: ₹45.39 Cr (0.70%) 0.0x
Free Float: ₹3,452.14 Cr (1.31% of FF traded)
Volume · 60D trend
39.09 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +14.0% | +9.0% | +8.0% | -- | +9.0% | Stable |
| ROE | +12.0% | +10.0% | +10.0% | -- | -- | Stable |
| Return | +11.0% | +3.0% | +31.0% | +20.0% | -- | Stable |
| Profit | +16.0% | -5.0% | +24.0% | -- | +27.0% | Accelerating |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 570 | 485 | 484 | 412 | 425 | 466 | 453 | 438 | 455 | 423 | 445 | 422 | 401 | 364 | 348 | 403 |
| Expenses | 488 | 460 | 438 | 381 | 401 | 424 | 417 | 394 | 404 | 375 | 394 | 388 | 375 | 348 | 328 | 374 |
| Operating Profit | 83 | 24 | 46 | 31 | 24 | 42 | 36 | 44 | 52 | 48 | 51 | 34 | 26 | 16 | 21 | 29 |
| Other Income | 5 | 8 | 4 | 30 | 4 | 5 | 5 | 5 | 3 | 4 | 4 | 3 | 2 | 3 | 1 | 1 |
| Interest | 5 | 4 | 4 | 4 | 4 | 5 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 0 |
| Depreciation | 8 | 6 | 10 | 11 | 9 | 16 | 5 | 2 | 6 | 10 | 8 | 8 | 8 | 7 | 7 | 7 |
| Profit Before Tax | 75 | 23 | 35 | 46 | 16 | 26 | 35 | 46 | 48 | 42 | 44 | 29 | 21 | 11 | 14 | 22 |
| Tax % | 24.0% | 33.0% | 22.0% | 10.0% | 26.0% | 21.0% | 24.0% | 24.0% | 25.0% | 32.0% | 27.0% | 26.0% | 29.0% | 26.0% | 36.0% | 29.0% |
| Net Profit | 56 | 16 | 28 | 41 | 11 | 20 | 27 | 35 | 36 | 29 | 32 | 21 | 15 | 8 | 9 | 16 |
| Exceptional Items | 0 | 0 | 0 | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 1.0 | 0.3 | 0.5 | 0.8 | 0.2 | 0.4 | 0.5 | 0.6 | 0.7 | 0.6 | 0.6 | 0.4 | 0.3 | 0.2 | 0.2 | 0.3 |
| Sales Growth (YoY) | 34.1% | 4.1% | 6.8% | -5.9% | -6.6% | 10.2% | 1.8% | 3.8% | 13.5% | 16.2% | 27.9% | 4.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 17.5% | 0.2% | 17.5% | -3.1% | -8.8% | 2.9% | 3.4% | -3.7% | 7.6% | -4.9% | 5.5% | 5.2% | 10.2% | 4.6% | -13.7% | -- |
| OP Growth (YoY) | 245.8% | -42.9% | 27.8% | -29.5% | -53.8% | -12.5% | -29.4% | 29.4% | 100.0% | 200.0% | 142.9% | 17.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | 245.8% | -47.8% | 48.4% | 29.2% | -42.9% | 16.7% | -18.2% | -15.4% | 8.3% | -5.9% | 50.0% | 30.8% | 62.5% | -23.8% | -27.6% | -- |
| Profit Growth (YoY) | -- | -22.5% | 3.1% | -49.0% | -70.3% | -28.1% | -16.6% | 63.9% | 147.2% | 243.2% | 255.8% | 34.5% | 159.9% | -33.1% | -58.2% | -57.7% |
| EPS Growth (YoY) | 415.0% | -21.6% | 2.0% | 17.2% | -71.8% | -32.7% | -22.2% | 52.4% | 144.8% | 243.8% | 250.0% | 35.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 255.2% | -42.0% | -33.3% | 275.0% | -46.0% | -24.5% | -23.4% | -9.9% | 29.1% | -12.7% | 50.0% | 44.8% | 81.3% | -11.1% | -41.9% | -- |
| OP Margin | 14.6% | 5.0% | 9.5% | 7.5% | 5.7% | 9.0% | 8.0% | 10.1% | 11.4% | 11.3% | 11.5% | 8.1% | 6.5% | 4.4% | 6.0% | 7.2% |
| Net Margin | 9.8% | 3.3% | 5.8% | 9.9% | 2.6% | 4.3% | 6.0% | 8.0% | 7.9% | 6.9% | 7.2% | 5.0% | 3.7% | 2.2% | 2.6% | 4.0% |
| Material Cost % | -- | 62.0% | 61.0% | 64.0% | 62.0% | 68.0% | 64.0% | 62.0% | 62.0% | 61.0% | 61.0% | 65.0% | 65.0% | 66.0% | 66.0% | 68.0% |
| Employee Cost % | -- | 12.0% | 13.0% | 14.0% | 13.0% | 12.0% | 12.0% | 11.0% | 11.0% | 11.0% | 11.0% | 10.0% | 11.0% | 12.0% | 11.0% | 10.0% |
| P/S | 3.30 | 1.75 | 1.34 | 1.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 45.79 | 33.13 | 24.04 | 24.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.17 | 2.53 | 2.00 | 2.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Morepen Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve financial results for ....
Please find attached the disclosure
Closure of Trading Window for the quarter ended 30 September 2026
Please find attached the file
Business Update-First Phase of Manufacturing Capacity Expansion Completed Ahead of Schedule
Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-26
Please find attached the specimen letter
Please find attached the BRSR for the financial year ended March 31, 2026
Please find attached the Annual Report for the financial year 2025-26 along with notice of 41st AGM
Please find enclosed notice of 41st AGM scheduled to be held on Saturday 26th September 2026 at 1:00 p.m. through VC/OAVM.
Newspaper publication-information relating to 41st Annual General Meeting, Dividend and record date
Allotment of equity shares by Morepen RX Limited, wholly owned subsidiary of the company
Please find attached the Q1 FY 27 Financial Results
Please find attached the file
Please find attached the Q1 FY 27 Financial Results
The name of wholly owned subsidiary company has been changed from Morepen Labs - FZCO to Morepen Labs FZE
Change in Senior Management Personnel on account of Resignation
Please find enclosed the Press Release
Elevation and change in designation of Mr. Sanjay Suri
closure of trading window for DP and their immediate relatives for the quarter ended 30 June 2026
The Exchange has sought clarification from Morepen Laboratories Ltd on June 10, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
Please find enclosed the reply
Newspaper Publication- Q4 and FY 26 Financial Results
Please find enclosed Investor Presentation on Q4 & FY26 Results
Please find enclosed press release
Please find attached the file
Re-appointment of Cost Auditors of the Company
Please find attached the file
Please find attached the file
Please find attached outcome of Board meeting
The Board Meeting to be held on 22/05/2026 has been revised to 26/05/2026 The Board Meeting to be held on 22/05/2026 has been revised to 26/05/2026
Please find attached the file
Morepen Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve Q-4 and FY 2026 Results.
Please find enclosed Annual Secretarial Compliance Report for the financial year ended on March 31, 2026.
Please find attached the monitoring agency report for the quarter ended March 31 2026
Execution of loan agreement with Shinhan Bank
Please find enclosed press release
Newspaper Advertisement regarding Special Window for transfer and dematerialization of physical shares
Closure of Trading Window for DP and their immediate relatives for the quarter ended 31 March 2026
Please find attached the file
Execution of loan agreement and other related documents with KEB Hana Bank
Please find attached the file
Please find enclosed press release
Execution of Loan Agreement and other related documents with Woori Bank
Please find attached the file
Newspaper Publication-Financial Results Q3 and Nine Months FY26
Please find attached the Monitoring Agency Report for the quarter ended 31 December 2025
Please find attached IP on Q3 and Nine Months FY26 Results
Please find attached the Q3 and Nine Months FY26 Results
Please find attached the Q3 and Nine Months FY26 Results
Annual Reports
15Credit Ratings
1Concalls
36Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Jul 2022
31 Jul 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Jul 2021
31 Jul 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Sep 2020
30 Sept 2020Jul 2020
31 Jul 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019May 2019
31 May 2019Feb 2019
28 Feb 2019Nov 2018
30 Nov 2018Aug 2018
31 Aug 2018Aug 2018
31 Aug 2018Jun 2018
30 Jun 2018May 2018
31 May 2018Feb 2018
28 Feb 2018Held by ETFs
1 ETFs hold MOREPENLAB · sorted by weight
Held by Mutual Funds
2 schemes hold MOREPENLAB · sorted by weight